High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C.
Int J Mol Sci. 2019 Feb 22;20(4):952. doi: 10.3390/ijms20040952.
Ovarian High-Grade Serous Carcinoma: Assessing Pathology for Site of Origin, Staging and Post-neoadjuvant Chemotherapy Changes.
Casey L, Singh N.
Surg Pathol Clin. 2019 Jun;12(2):515-528. doi: 10.1016/j.path.2019.01.007.
Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study.
Takamatsu S, Hillman RT, Yoshihara K, Baba T, Shimada M, Yoshida H, Kajiyama H, Oda K, Mandai M, Okamoto A, Enomoto T, Matsumura N.
Br J Cancer. 2024 Nov;131(8):1340-1349. doi: 10.1038/s41416-024-02837-x. Epub 2024 Aug 30.
High-grade serous carcinoma of tubo-ovarian origin: recent developments.
Singh N, McCluggage WG, Gilks CB.
Histopathology. 2017 Sep;71(3):339-356. doi: 10.1111/his.13248. Epub 2017 Jul 18.
Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, Le ND, Gilks CB, Singh N.
J Clin Oncol. 2015 Aug 1;33(22):2457-63. doi: 10.1200/JCO.2014.60.5212. Epub 2015 Jun 29.
High-Grade Serous Ovarian Carcinoma in the Genomics Era: Current Applications, Challenges and Future Directions.
Lewis ME, Caricato C, Roberts HL, Ganesan S, Seksaf NA, Maniati E, Sideris M.
Int J Mol Sci. 2026 Feb 6;27(3):1617. doi: 10.3390/ijms27031617.
Single-cell transcriptomics reveals the aggressive landscape of high-grade serous carcinoma and therapeutic targets in tumor microenvironment.
Xu J, Lu W, Wei X, Zhang B, Yang H, Tu M, Chen X, Wu S, Guo T.
Cancer Lett. 2024 Jul 1;593:216928. doi: 10.1016/j.canlet.2024.216928. Epub 2024 May 5.
Ovarian cancer metastasis: Looking beyond the surface.
Bayraktar E, Chen S, Corvigno S, Liu J, Sood AK.
Cancer Cell. 2024 Oct 14;42(10):1631-1636. doi: 10.1016/j.ccell.2024.08.016. Epub 2024 Sep 12.
The genomic trajectory of ovarian high-grade serous carcinoma can be observed in STIC lesions.
Cheng Z, Ennis DP, Lu B, Mirza HB, Sokota C, Kaur B, Singh N, Le Saux O, Russo G, Giannone G, Tookman LA, Krell J, Barnes C, McDermott J, McNeish IA.
J Pathol. 2024 Sep;264(1):42-54. doi: 10.1002/path.6322. Epub 2024 Jul 2.
Clinical commentary: Extra-uterine high-grade serous carcinoma: two pathways, two preventions?
Crum CP, Yoon JY, Feltmate CM.
Gynecol Oncol. 2023 Feb;169:1-3. doi: 10.1016/j.ygyno.2022.11.019. Epub 2022 Nov 29.
